Arecor Therapeutics PLC ARECOR COLLABORATES WITH TOP GLOBAL PHARMA COMPANY (0563P)

TIDMAREC

RNS Number : 0563P

Arecor Therapeutics PLC

16 June 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH A TOP 5 GLOBAL PHARMACEUTICAL COMPANY

Development of stable injectable high concentration formulations for its proprietary products

Cambridge, UK, 16 June 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with a top five global pharmaceutical company.

Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat(TM), to develop improved, stable, high concentration liquid formulations of its proprietary products. The Company will fund the initial development work and has the option to acquire the rights to the new proprietary formulations and associated intellectual property under a technology licensing model.

Sarah Howell, Chief Executive Officer of Arecor, said: "This collaboration expands our partner portfolio of high-profile pharmaceutical companies. The growing recognition of how the Arestat(TM) platform can enhance a broad range of therapeutic products is testament to our expertise and innovation in formulation science. For our partners, we are able to significantly improve their products to enable patient friendly treatment regimens that are effective, safe and more convenient, which in turn can lead to better adherence and health outcomes, benefitting healthcare systems as a whole."

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc                    www.arecor.com 
 Dr Sarah Howell, Chief Executive Officer   Tel: [phone] 
                                             Email: [e-mail] 
 
 Susan Lowther, Chief Financial Officer     Tel: [phone] 
                                             Email: [e-mail] 
 
 Mo Noonan, Communications                  Tel: [phone] 
                                             Email: [e-mail] 
 
 Panmure Gordon (UK) Limited (NOMAD         Tel: [phone] 
  and Broker) 
  Freddy Crossley, Emma Earl (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications 
 Chris Gardner, David Daley, Angela         Tel: [phone] 
  Gray                                       Email: [e-mail] 
 

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM), we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat(TM) platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFAMLTMTBBBJT

(END) Dow Jones Newswires

June 16, 2022 02:00 ET (06:00 GMT)